Evaluation of 2‐Hour Post‐Dose Efficacy of Lasmiditan for the Acute Treatment of Difficult‐to‐Treat Migraine Attacks-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Evaluation of 2‐Hour Post‐Dose Efficacy of Lasmiditan for the Acute Treatment of Difficult‐to‐Treat Migraine Attacks

Published:2020-07-07 Issue:8 Volume:60 Page:1601-1615
ISSN:0017-8748
Container-title:Headache: The Journal of Head and Face Pain
language:en
Short-container-title:Headache: The Journal of Head and Face Pain

Author:

Tepper Stewart J.¹,Vasudeva Raghavendra²,Krege John H.²,Rathmann Suchitrita S.²,Doty Erin²,Vargas Bert B.²³,Magis Delphine⁴,Komori Mika⁵

Affiliation:

1. Department of Neurology Geisel School of Medicine at Dartmouth Hanover NH USA

2. Eli Lilly and Company, Indianapolis IN USA

3. University of Texas Southwestern Medical Center Dallas TX USA

4. Department of Neurology and Headache and Pain Multimodal Management Clinic CHR East Belgium Hospital Verviers Belgium

5. Eli Lilly and Company Kobe Japan

Funder

Eli Lilly and Company

Publisher

Wiley

Subject

Clinical Neurology,Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/head.13897

Reference43 articles.

1. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition

2. The Acute Treatment of Migraine in Adults: The American Headache Society Evidence Assessment of Migraine Pharmacotherapies

3. Acute Migraine Treatment in Adults

4. Predicting Inadequate Response to Acute Migraine Medication: Results From the American Migraine Prevalence and Prevention (AMPP) Study

5. Predicting the response to sumatriptan: The Sumatriptan Naratriptan Aggregate Patient Database

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pituitary cyclase‐activating polypeptide targeted treatments for the treatment of primary headache disorders;Annals of Clinical and Translational Neurology;2024-06-18

2. An update on pharmacotherapy for trigeminal neuralgia;Expert Review of Neurotherapeutics;2024-06-13

3. Efficacy and tolerability of 100 mg of lasmiditan for migraine: A multi-center, prospective observational real-world study in Japan;Cephalalgia;2024-06

4. 5-HT1F agonists;Handbook of Clinical Neurology;2024

5. Profile of Lasmiditan in the Acute Treatment of Migraine in Adults: Design, Development, and Place in Therapy;Drug Design, Development and Therapy;2023-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3